The credit rating agency Crisil Ratings Limited has continued its ratings on the bank facilities and non-convertible debentures of the Company.

Filed: 31 Aug 2026, 20:12 IST Exchange: BSE Category: Regulatory Compliance — Credit Rating

Crisil Ratings Limited has continued its ratings on Anupam Rasayan India Limited's bank facilities and non-convertible debentures, maintaining Long Term rating at Crisil A+/Watch Developing and Short Term rating at Crisil A1/Watch Developing. The ratings remain on watch due to the ongoing acquisition of a 43.3-48.2% stake in Bliss GVS Pharma, expected to complete in September 2026. The acquisition funding mix of debt and equity is critical, with debt of Rs 300 crore planned. The company's business risk profile is stable with revenue growth to Rs 2,365 crore in fiscal 2026 and a healthy financial risk profile. Working capital cycle improved but remains large. Liquidity is strong with cash of Rs 378 crore as of March 31, 2026.

Source: Original filing PDF — view on exchange portal

⚡ You're reading this after the fact — subscribers got it instantly

ISA

Indian Stock Alerts BOT

🚨 ANURAS — Quarterly Results

Revenue: ₹2,35,800 Cr (+12% YoY)

PAT: ₹19,200 Cr (+17% YoY)

EBITDA margin: 16.8%

Board declared ₹10/share dividend. Jio adds 8M subs.

📎 bseindia.com/xml-data/...

🎧 Audio summary ready

✓✓ 6:47 PM

🎧

Instant audio summaries2-min AI concall recap delivered with every earnings alert

📊

20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings

🔍

Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically

⚡

Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add ANURAS to your watchlist — all of this, automated.

14-day Pro trial · No credit card · Cancel anytime

More on Anupam Rasayan India Limited

Important. The summary above is generated automatically from Anupam Rasayan India Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.